Related Experiment Video
Updated: Aug 22, 2026

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training
Published on: January 29, 2017
Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects
1Department of Anesthesia & Critical Care, Pritzker School of Medicine, The University of Chicago, 5841 S. Maryland Avenue, MC 4028, Chicago, IL 60637, USA. cyuan@airway.uchicago.edu
Abstract:
Opioids are associated with a number of adverse effects, constipation being the most common long-term adverse effect in patients with advanced cancer. Significant progress has been made over the past several decades in understanding the mechanisms of action of opioid compounds; however, these advances have yielded few new treatments for the bowel dysfunction caused by opioids. Methylnaltrexone, the first peripheral opioid receptor antagonist and currently under clinical investigation, has the potential to prevent or treat opioid-induced peripherally mediated side effects, such as constipation, without interfering with analgesia. This article reviews existing clinical data on methylnaltrexone, focusing on the antagonism of opioid-induced adverse effects in the gut.
Insights
Methylnaltrexone offers a novel approach to managing opioid-induced constipation in cancer patients. This peripherally acting drug targets opioid receptors in the gut, alleviating side effects without compromising pain relief.
Area of Science:
- Gastroenterology
- Pharmacology
- Oncology
Background:
- Opioids are commonly prescribed for pain management, particularly in advanced cancer.
- Opioid-induced constipation (OIC) is a frequent and distressing adverse effect.
- Current treatments for OIC are limited and often ineffective.
Purpose of the Study:
- To review the clinical data on methylnaltrexone.
- To evaluate methylnaltrexone's efficacy in treating opioid-induced bowel dysfunction.
- To assess methylnaltrexone's safety profile and impact on analgesia.
Main Methods:
- Review of existing clinical trial data.
- Focus on studies investigating methylnaltrexone's peripheral opioid receptor antagonism.
- Analysis of outcomes related to gastrointestinal side effects and pain management.
Main Results:
- Methylnaltrexone selectively antagonizes peripheral opioid receptors.
- Clinical data suggest methylnaltrexone effectively alleviates OIC.
- Methylnaltrexone does not appear to interfere with central opioid analgesia.
Conclusions:
- Methylnaltrexone represents a promising therapeutic option for OIC.
- Its peripheral action mechanism offers a way to manage OIC without affecting pain control.
- Further clinical investigation is warranted to establish its role in patient care.
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Analgesia and Pain Management
Opioid Analgesics: Morphine and Other Natural Cogeners
Opioid Receptors: Overview
Pharmaceutical Poisoning: Treatment Strategies
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
